Generation and purification of iPSC-derived cardiomyocytes for clinical applications.

ABSTRACT:

Background

Over the past decade, the field of cell therapy has rapidly expanded with the aim to replace and repair damaged cells and/or tissue. Depending on the disease many different cell types can be used as part of such a therapy. Here we focused on the potential treatment of myocardial infarction, where currently available treatment options are not able to regenerate the loss of healthy heart tissue.

Method

We generated good manufacturing practice (GMP)-compatible cardiomyocytes (iCMs) from transgene- and xenofree induced pluripotent stem cells (iPSCs) that can be seamless adapted for clinical applications. Further protocols were established for replating and freezing/thawing iCMs under xenofree conditions.

Results

iCMs showed a cardiac phenotype, with the express

SUBMITTER: Generali M 

PROVIDER: S-EPMC12008852 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature